Brian Ball, M.D.
It is an exciting time to be at City of Hope as it stands at the forefront of cancer discovery.
2010-2014, M.D., Doctor of Medicine, cum laude, Georgetown University School of Medicine, Washington, DC
2009-2010, M.D., Physiology and Biophysics, Georgetown University, Washington, DC
2002-2006, B.S., Biology, Minor in German Studies, Boston College, Chestnut Hill, MA
2017-2020, Hematology-Oncology Fellowship, Memorial Sloan Kettering Cancer Center, New York, NY
2014-2017, Internal Medicine Residency, Yale-New Haven Hospital, New Haven, CT
2011, Research Internship, Brigham and Women’s Hospital, Hematology and Oncology Department, Boston, MA
2020-present, Assistant Professor, Division of Leukemia, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA
2015-2017, Myelodysplastic Syndromes Research, Hematology and Oncology Department, Yale University, New Haven, CT
2013-2014, Gastrointestinal Malignancies Research, Hematology and Oncology Department, Georgetown University, Washington, DC
2006-2009, Research Technician, Hematology and Oncology Department, Brigham and Women’s Hospital, Boston, MA
2020, Mortimer J. Lacher Fellowship Funding from the Lymphoma Foundation
2019-2020, Memorial Sloan Kettering Cancer Center Chief Fellow
2019, American Society of Hematology Abstract Achievement Award for the ASH Annual Meeting
2016, American Society of Hematology Abstract Achievement Award for the ASH Annual Meeting
2017, Yale/Stanford Global Health Scholar Recipient
2014, Alpha Omega Alpha
2014, The Jesuit Leadership and Service Award
2014, Michael J. Caruso, MD Memorial Award
2013, Read Poster Recipient, Awarded to members of Georgetown exemplifying “Cura Personalis”
Memorial Sloan Kettering Cancer Center Certificate Program in Clinical Investigation
- Ball B, Stein EM. Which are the most promising targets for minimal residual disease-directed therapy in acute myeloid leukemia prior to allogeneic stem cell transplant? Haematologica. 104 (8): 1521: 1531. 2019. PMID: 31366466
- Ball B, Abdel-Wahab O. Activating p53 and Inhibiting Superenhancers to Cure Leukemia. Trends in Pharmacological Sciences. 39 (12): 1002-1004. 2018. PMID: 27654579
- Ball B, Komrokji RS, Ades L, Sekeres MA, DeZern AE, Pleyer L, Vey N, Almeida A, Germing U, Cluzeau T, Platzbecker U, Gore S, Fenaux P, Prebet T. Evaluation of induction chemotherapy regimens in myelodysplastic syndromes and acute myeloid leukemia after hypomethylating agent failure. Blood Advances. 2 (16): 2063-2071. 2018. PMID: 30120104
- Ball B, Zeidan A, Gore SD, Prebet T. Hypomethylating agent combination strategies in myelodysplastic syndromes: Hopes and shortcomings. Leukemia and Lymphoma. 58: 1022-36. 2017. PMID: 27654579
- Kumar MS, Narla A, Nonami A, Mullally A, Dimitrova N, Ball B, McAuley JR, Poveromo L, Kutok JL, Galili N, Raza A, Attar E, Gilliland DG, Jacks T, Ebert BL. Coordinate loss of a microRNA and protein-coding gene cooperate in the pathogenesis of 5q- syndrome. Blood. 118(17):4666-73. 2011. PMID: 21873545
- Kharas MG, Lengner CJ, Al-Shahrour F, Bullinger L, Ball B, Zaidi S, Morgan K, Tam W, Paktinat M, Okabe R, Gozo M, Einhorn W, Lane SW, Scholl C, Frohling S, Fleming M, Ebert BL, Gilliland DG, Jaenisch R, Daley GQ. Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia. Nat Med. 16:903-908. 2010. PMID: 20616797
- Mullally A, Lane SW, Ball B, Megerdichian C, Okabe R, Al-Shahrour F, Paktinat M, Haydu JE, Housman E, Lord AM, Wernig G, Kharas MG, Mercher T, Kutok JL, Gilliland DG, Ebert BL. Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer Cell. 17:584-596. 2010. PMID: 20541703
- Koo S, Huntly B, Wang Y, Chen J, Brumme K, Ball B, McKinney-Freeman S, Yabuuchi A, Scholl C, Bansal D, Zon L, Froehling S, Daley G, Gilliland G, Mercher T. Cdx4 is dispensable for murine adult hematopoietic stem cells but promotes MLL-AF9-mediated leukemogenesis. Haematologica. 2010. PMID: 20494928;
- Cornejo MG, Kharas MG, Werneck MB, Le Bras S, Moore SA, Ball B, Beylot-Barry M, Rodig SJ, Aster JC, Lee BH, Cantor H, Merlio JP, Gilliland DG, Mercher T. Constitutive JAK3 activation induces lymphoproliferative syndromes in murine bone marrow transplantation models. Blood. 113:2746-2754. 2009. PMID: 19139084